A “cookie cutter” technique for COVID drug discovery

“Beyond COVID-19, we believe SMAs have huge potential to unblock constrictions in the drug pipeline.”
| 2 min read

BIRMINGHAM, UK—University of Birmingham researchers are working to isolate and extract the COVID-19 encounter complex in a form that is stable enough for identification of target sites for future antiviral drugs.

The encounter complex is formed when the COVID-19 spike latches onto a binding site on an ACE-2 receptor, which is a complex protein embedded in cell membranes in the lungs, as well as cells that line the nose and airways.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Scientific illustration of a cell releasing exosomes: small, spherical extracellular vesicles budding from and detaching off the cell’s plasma membrane into the surrounding space, shown as tiny capsule-like structures emerging from the cell surface.
Learn how to distinguish true extracellular vesicles from similarly sized particles using affinity capture and immunofluorescence.
Close-up of a scientist’s hands typing on a laptop next to a microscope in a laboratory setting.
Explore how a needs-driven approach to electronic laboratory notebook selection can improve data integrity, reproducibility, and scientific continuity.
Scientist weighing a laboratory sample using a four-decimal analytical balance in a quality control setting.
Learn the fundamental weighing principles and operational controls that support reliable sample preparation.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue